Targeting the gut and tumor microbiome in cancer treatment resistance
American Journal of Physiology-Cell Physiology · 2024
DOI: 10.1152/ajpcell.00201.2024 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Physiology-Cell Physiology, 2024. Verfasst von Sona Ciernikova und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Gastrointestinal Microbiome, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 184 Literaturangaben. Gefördert von: Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences (VEGA), Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences.
Abstract (Originalsprache)
Therapy resistance represents a significant challenge in oncology, occurring in various therapeutic approaches. Recently, animal models and an increasing set of clinical trials highlight the crucial impact of the gut and tumor microbiome on treatment response. The intestinal microbiome contributes to cancer initiation, progression, and formation of distant metastasis. In addition, tumor-associated microbiota is considered a critical player in influencing tumor microenvironments and regulating local immune processes. Intriguingly, numerous studies have successfully identified pathogens within the gut and tumor microbiome that might be linked to a poor response to different therapeutic modalities. The unfavorable microbial composition with the presence of specific microbes participates in cancer resistance and progression via several mechanisms, including upregulation of oncogenic pathways, macrophage polarization reprogramming, metabolism of chemotherapeutic compounds, autophagy pathway modulation, enhanced DNA damage repair, inactivation of a proapoptotic cascade, and bacterial secretion of extracellular vesicles, promoting the processes in the metastatic cascade. Targeted elimination of specific intratumoral bacteria appears to enhance treatment response. However, broad-spectrum antibiotic pretreatment is mostly connected to reduced efficacy due to gut dysbiosis and lower diversity. Mounting evidence supports the potential of microbiota modulation by probiotics and fecal microbiota transplantation to improve intestinal dysbiosis and increase microbial diversity, leading to enhanced treatment efficacy while mitigating adverse effects. In this context, further research concerning the identification of clinically relevant microbiome signatures followed by microbiota-targeted strategies presents a promising approach to overcoming immunotherapy and chemotherapy resistance in refractory patients, improving their outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, Bratislava, Slovakia.
- 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia.
ORCID-Profile: Sona Ciernikova
Förderung
- Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences (VEGA)
- Ministry of Education, Science, Research and Sport of the Slovak Republic and Slovak Academy of Sciences
Zitieren
APA
Ciernikova, S., Sevcikova, A., & Mego, M. (2024). Targeting the gut and tumor microbiome in cancer treatment resistance. American Journal of Physiology-Cell Physiology. https://doi.org/10.1152/ajpcell.00201.2024
Vancouver
Ciernikova S, Sevcikova A, Mego M. Targeting the gut and tumor microbiome in cancer treatment resistance. American Journal of Physiology-Cell Physiology. 2024. doi:10.1152/ajpcell.00201.2024
BibTeX
@article{Ciernikova2024,
author = {Ciernikova, Sona and Sevcikova, Aneta and Mego, Michal},
title = {Targeting the gut and tumor microbiome in cancer treatment resistance},
journal = {American Journal of Physiology-Cell Physiology},
year = {2024},
doi = {10.1152/ajpcell.00201.2024}
}
EUVIMED